Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
Formosa Pharmaceutic
Read More
生物技術
OBI Pharma announces acquisition of cancer drug candidate from Threshold Pharmaceuticals
Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Read More
Taiwan a great location for biotech IPOs, says Aslan Pharma CEO
In an interview with finance website Deal Street Asia, Singapore-headquartered drug development firm Asian Pharmaceuticals’ CEO Dr Carl Firth discussed why he took the company public in Taiwan and not Singapore, Europe or the US.
Read More
US pharma lobby group pushes for better IP protection in Taiwan
A delegation from the Pharmaceutical Research and Manufacturers of America (PhRMA) made a recent visit to Taiwan and while here urged the government to pass laws that would better strengthen intellectual property protection for pharmaceuticals.
Read More